|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
02607 SH PHARMA
Nominal 
11.510 -0.030 (-0.260%) | 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Turnover | 147,469,729 | 4.151% | 283,579,601 | 275,250,935 | 260,295,089 | 231,981,300 |
| Cost of Sales | (131,209,437) | 3.592% | -- | -- | -- | -- |
| Gross Profit | 16,260,293 | 8.890% | -- | -- | -- | -- |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | (533,920) | -29.590% | (1,261,143) | (636,682) | (436,505) | (425,194) | |
| Profit / (Loss) on Disposal | 179,700 | 349.402% | 157,153 | 187,968 | 92,475 | 1,438,918 | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | 48,792 | -87.182% | 284,473 | 521,909 | 129,329 | 526,743 | |
| Profit / (Loss) before Taxation | 5,631,383 | -17.438% | 9,819,805 | 8,020,007 | 7,054,297 | 8,808,353 | |
| Taxation | (1,289,727) | -29.370% | (2,846,087) | (2,149,995) | (1,887,726) | (1,816,339) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (837,209) | 56.219% | (1,249,160) | (1,317,483) | (1,398,571) | (1,374,863) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 3,504,447 | -21.405% | 5,724,558 | 4,552,528 | 3,768,000 | 5,617,152 | |
| 2026/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2025/12 RMB(K¥) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 694,509 | -7.371% | 1,407,224 | 1,480,912 | 1,485,758 | 1,313,192 |
| Depreciation & Amortisation | 1,518,858 | 3.678% | 3,060,610 | 2,609,899 | 2,379,459 | 2,417,627 |
| Directors' Emoluments | -- | -- | 7,737 | 6,708 | 18,467 | 20,595 |
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2026/06 - Interim | %Chg (Compare to Interim) | 2025/12 | 2024/12 | 2023/12 | 2022/12 | |
| EPS (cts) | 95.000 | -20.833% | 154.000 | 123.000 | 102.000 | 161.000 |
| DPS (cts) | 10.000 | -- | 47.000 | 37.000 | 41.000 | 61.000 |
| Dividend Payout Ratio (%) | 10.526% | -- | 30.519% | 30.081% | 40.196% | 37.888% |
| Cash flow per share ($) | -- | -- | 1.660 | 1.573 | 1.413 | 1.362 |
| NBV per share ($) | 21.127 | -- | 20.465 | 19.330 | 18.504 | 18.137 |
| Remarks: | Real time quote last updated: 09/09/2026 17:53 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 3,504,447 |
| %Change | -21.405% |
| EPS / (LPS) | RMB 0.950 |
| NBV Per Share (¥) | RMB 21.127 |